Advances in radiotherapy

BMJ (Online)

Volumn 345, Issue 7886, 2012, Pages

  Ahmad, Saif S ^a   Duke, Simon ^a   Jena, Rajesh ^a   Williams, Michael V ^a   Burnet, Neil G ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; DNA DAMAGE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GENERAL PRACTITIONER; HEAD AND NECK CANCER; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PHOTON; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON THERAPY; RADIATION ABSORPTION; RADIATION DOSE; RADIOLOGICAL PROCEDURES; REVIEW; SAFETY; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; TREATMENT PLANNING;

GREAT BRITAIN; HUMANS; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PROTON THERAPY; RADIOSURGERY; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84870713914     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7765     Document Type: Review

References (37)

1. Tubiana M. The role of local treatment in the cure of cancer. Eur J Cancer 1992;28A:2061-9.
2. Department of Health. Radiotherapy dataset annual report 2009/2010. 2011. www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-128357.
3. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72. (Pubitemid 29088118)
4. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129-37. (Pubitemid 41278947)
5. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2012;24:112-24.
6. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 suppl):S10-9.
7. Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapy-related fatigue. Crit Rev Oncol Hematol 2002;41:317-25. (Pubitemid 34203667)
8. Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 2010;11:231-40.
9. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007;8:1007-17. (Pubitemid 47629896)
10. Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 2012;104:357-70.
11. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39. (Pubitemid 27419206)
12. Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220-6.
13. Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a national cohort study. J Clin Oncol 2012;30:2745-52.
14. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-55. (Pubitemid 23312611)
15. Miller MC, Agrawal A. Hypothyroidism in postradiation head and neck cancer patients: incidence, complications, and management. Curr Opin Otolaryngol Head Neck Surg 2009;17:111-5.
16. Marks LB, Rose CM, Hayman JA, Williams TR. The need for physician leadership in creating a culture of safety. Int J Radiat Oncol Biol Phys 2011;79:1287-9.
17. Williams MV, Frew TL. How dangerous is radiotherapy? Int J Radiat Oncol Biol Phys 2011;79:1601.
18. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127-36.
19. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2010;22:643-57.
20. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8. (Pubitemid 36403679)
21. Ruben JD, Davis S, Evans C, Jones P, Gagliardi F, Haynes M, et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 2008;70:1530-6.
22. AlDuhaiby EZ, Breen S, Bissonnette JP, Sharpe M, Mayhew L, Tyldesley S, et al. A national survey of the availability of intensity-modulated radiation therapy and stereotactic radiosurgery in Canada. Radiat Oncol 2012;7:18.
23. Mayles WP, Cooper T, Mackay R, Staffurth J, Williams M. Progress with intensity-modulated radiotherapy implementation in the UK. Clin Oncol (R Coll Radiol) 2012;24:543-4.
24. Jefferies S, Taylor A, Reznek R. Results of a national survey of radiotherapy planning and delivery in the UK in 2007. Clin Oncol (R Coll Radiol) 2009;21:204-17.
25. Williams MV, Cooper T, Mackay R, Staffurth J, Routsis D, Burnet N. The implementation of intensity-modulated radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2010;22:623-8.
26. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-108, iii-iv.
27. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007;7:949-60. (Pubitemid 350165868)
28. Button MR, Staffurth JN. Clinical application of image-guided radiotherapy in bladder and prostate cancer. Clin Oncol (R Coll Radiol) 2010;22:698-706.
29. Short S, Tobias J. Radiosurgery for brain tumours. BMJ 2010;340:c3247.
30. Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010;22:157-72.
31. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systematic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94:1-11.
32. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007;25:953-64. (Pubitemid 350002861)
33. Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012;103:8-11.
34. Brodin NP, Vogelius IR, Maraldo MV, Munck Af Rosenschold P, Aznar MC, Kiil-Berthelsen A, et al. Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 2012;118:5432-40.
35. DeLaney TF. Proton therapy in the clinic. Front Radiat Ther Oncol 2011;43:465-85.
36. Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, et al. Radiotherapy research priorities for the UK. Clin Oncol (R Coll Radiol) 2010;22:707-9.
37. Burnet NG, Billingham LJ, Chan CS, Hall E, Macdougall J, Mackay RI, et al; on behalf of the National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group. Methodological considerations in the evaluation of radiotherapy technologies. Clin Oncol (R Coll Radiol) 2012; published online 12 July.